Literature DB >> 27843933

Onychomycosis: Practical Approaches to Minimize Relapse and Recurrence.

Antonella Tosti1, Boni E Elewski2.   

Abstract

INTRODUCTION: Toenail onychomycosis is a common disease in which treatment options are limited and treatment failures and disease recurrence are frequently encountered. It usually requires many months of treatment, and recurrence may occur in more than half of the patients within 1 year or more after the infection has been eradicated. Data on long-term treatment, follow-up and recurrence are limited.
OBJECTIVE: Our objective is to interpret these data and recommend practical approaches that should minimize recurrence based on our clinical experience.
RESULTS: Several factors have been suggested to play a role in the high incidence of recurrence, but only the extent of nail involvement and co-existing diabetes mellitus have been shown to have a significant impact.
CONCLUSION: The use of topical antifungals to prevent recurrences after complete cure was achieved has been suggested by various workers and used successfully in our practice. However, it has never been validated through clinical studies. Topical prophylaxis once weekly or twice monthly would seem appropriate in those patients most at risk. Prompt treatment of tinea pedis is essential, as is ensuring family members are free from disease. Patient education and pharmacologic intervention are equally important, and there are a number of simple strategies patients can employ. Managing onychomycosis is a significant long-term commitment for any patient, and minimizing recurrence is critical to meet their expectations.

Entities:  

Keywords:  Antifungal agents; Onychomycosis; Recurrence; Relapse; Topical prophylaxis

Year:  2016        PMID: 27843933      PMCID: PMC5096127          DOI: 10.1159/000448056

Source DB:  PubMed          Journal:  Skin Appendage Disord        ISSN: 2296-9160


  36 in total

1.  Ozone gas effectively kills laboratory strains of Trichophyton rubrum and Trichophyton mentagrophytes using an in vitro test system.

Authors:  A K Gupta; W Brintnell
Journal:  J Dermatolog Treat       Date:  2012-09-19       Impact factor: 3.359

2.  Dermatophyte isolation in the socks of patients with tinea pedis and onychomycosis.

Authors:  Alexandro Bonifaz; Denisse Vázquez-González; Marco Antonio Hernández; Javier Araiza; Andrés Tirado-Sánchez; Rosa María Ponce
Journal:  J Dermatol       Date:  2013-04-27       Impact factor: 4.005

3.  Factors influencing coexistence of toenail onychomycosis with tinea pedis and other dermatomycoses: a survey of 2761 patients.

Authors:  Jacek C Szepietowski; Adam Reich; Emilia Garlowska; Marzena Kulig; Eugeniusz Baran
Journal:  Arch Dermatol       Date:  2006-10

4.  Intermittent low dose itraconazole treatment for onychomycosis--long term follow-up.

Authors:  A Ingber
Journal:  Med Mycol       Date:  2001-12       Impact factor: 4.076

5.  Onychomycosis: a significant medical disorder.

Authors:  R K Scher
Journal:  J Am Acad Dermatol       Date:  1996-09       Impact factor: 11.527

6.  Arthroconidia production in Trichophyton rubrum and a new ex vivo model of onychomycosis.

Authors:  S Amir Yazdanparast; Richard C Barton
Journal:  J Med Microbiol       Date:  2006-11       Impact factor: 2.472

7.  Patients at risk of onychomycosis--risk factor identification and active prevention.

Authors:  A Tosti; R Hay; R Arenas-Guzmán
Journal:  J Eur Acad Dermatol Venereol       Date:  2005-09       Impact factor: 6.166

8.  Topical amorolfine for 15 months combined with 12 weeks of oral terbinafine, a cost-effective treatment for onychomycosis.

Authors:  R Baran
Journal:  Br J Dermatol       Date:  2001-10       Impact factor: 9.302

9.  Antifungal susceptibilities and genetic relatedness of serial Trichophyton rubrum isolates from patients with onychomycosis of the toenail.

Authors:  M C Bradley; S Leidich; N Isham; B E Elewski; M A Ghannoum
Journal:  Mycoses       Date:  1999       Impact factor: 4.377

10.  Sanitization of contaminated footwear from onychomycosis patients using ozone gas: a novel adjunct therapy for treating onychomycosis and tinea pedis?

Authors:  Aditya K Gupta; William C Brintnell
Journal:  J Cutan Med Surg       Date:  2013 Jul-Aug       Impact factor: 2.092

View more
  9 in total

1.  Early Visible Improvements during K101-03 Treatment: An Open-Label Multicenter Clinical Investigation in Patients with Onychomycosis and/or Nail Psoriasis.

Authors:  Bianca Maria Piraccini; Michela Starace; Anders Toft
Journal:  Dermatology       Date:  2017-08-05       Impact factor: 5.366

2.  Evaluation of Topical Antifungals Using a New Predictive Animal Model for Efficacy against Severe Tinea Unguium: A Comparison of Efinaconazole and Luliconazole.

Authors:  Akane Masumoto; Keita Sugiura; Yoshiki Matsuda; Haruki Tachibana; Yoshiyuki Tatsumi
Journal:  Mycopathologia       Date:  2022-09-12       Impact factor: 3.785

Review 3.  A Paradigm Shift in the Treatment and Management of Onychomycosis.

Authors:  Aditya K Gupta; Maanasa Venkataraman; Helen J Renaud; Richard Summerbell; Neil H Shear; Vincent Piguet
Journal:  Skin Appendage Disord       Date:  2021-05-11

Review 4.  Recent advances in therapies for onychomycosis and its management.

Authors:  Aditya K Gupta; Nadia Stec
Journal:  F1000Res       Date:  2019-06-25

5.  Molecular identification of Fusarium species complex isolated from clinical samples and its antifungal susceptibility patterns.

Authors:  Yashik Bansal; Nidhi Singla; Neelam Kaistha; Sunandan Sood; Jagdish Chander
Journal:  Curr Med Mycol       Date:  2019

Review 6.  Onychomycosis: An Updated Review.

Authors:  Alexander K C Leung; Joseph M Lam; Kin F Leong; Kam L Hon; Benjamin Barankin; Amy A M Leung; Alex H C Wong
Journal:  Recent Pat Inflamm Allergy Drug Discov       Date:  2020

Review 7.  Updated Perspectives on the Diagnosis and Management of Onychomycosis.

Authors:  Julianne M Falotico; Shari R Lipner
Journal:  Clin Cosmet Investig Dermatol       Date:  2022-09-15

Review 8.  Challenges and Opportunities in the Management of Onychomycosis.

Authors:  Julia K Christenson; Gregory M Peterson; Mark Naunton; Mary Bushell; Sam Kosari; Kavya E Baby; Jackson Thomas
Journal:  J Fungi (Basel)       Date:  2018-07-24

9.  NP213 (Novexatin®): A unique therapy candidate for onychomycosis with a differentiated safety and efficacy profile.

Authors:  Derry K Mercer; Jennifer C Robertson; Lorna Miller; Colin S Stewart; Deborah A O'Neil
Journal:  Med Mycol       Date:  2020-11-10       Impact factor: 4.076

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.